The role of serum adipocyte fatty acid-binding protein on the development of metabolic syndrome is independent of pro-inflammatory cytokines

The mAb against adipocyte fatty acid-binding protein 2E4 attenuates the inflammation in the mouse model of high-fat diet-induced obesity via toll-like receptor 4 pathway

“…These findings are also in line with a previous study by Cao et al (2013); (3) a previous report showed that >70% germline knockdown of A-FABP by RNA interference did not improve insulin sensitivity in diet-induced obese mice (Yang et al, 2011). Given that A-FABP is a highly abundant protein in the serum of obese individuals, the bar to achieve a sufficient neutralization by an antibody is high (Park et al, 2012;Xu et al, 2006). Although 2E4 shows high specificity to A-FABP in mouse adipose tissue, it may not be Fig.…”

Metabolic complications and selected cytokines in HIV‑infected individuals

“…14,31 Baseline serum FABP4 levels were considered to predict the risk for metabolic complications in HIV-infected patients. 13,32 FABP4 also correlated with glucose, insulin, and TG concentrations in our study. The reported differences may be associated with the fact that, unlike in our study, the previous studies recruited patients with obesity and metabolic complications.…”

High Serum Adipocyte Fatty Acid Binding Protein Is Associated with Metabolic Syndrome in Patients with Type 2 Diabetes

“…All of these results indicate that A-FABP has an important role in the development of major components of the MetS through its distinct actions in adipocytes and macrophages. Serum A-FABP levels predict the development of the MetS in a Chinese and a Korean cohort study [20, 21] and plasma A-FABP level was found to be a strong predictor of type 2 DM independently of the traditional risk factors including obesity, insulin resistance, or glycemic indexes [22]. Cabré et al noted A-FABP levels positively correlated to the MetS in type 2 DM subjects [23].…”